DSpace logo

Please use this identifier to cite or link to this item: http://142.54.178.187:9060/xmlui/handle/123456789/12231
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKHAN, S.-
dc.contributor.authorANJUM, S.-
dc.contributor.authorBAIG, S.M.-
dc.contributor.authorKHANUM, A.-
dc.contributor.authorHAIDER, M.Z.-
dc.contributor.authorQAZI, M.H.-
dc.date.accessioned2021-01-19T06:41:07Z-
dc.date.available2021-01-19T06:41:07Z-
dc.date.issued1991-09-01-
dc.identifier.urihttp://142.54.178.187:9060/xmlui/handle/123456789/12231-
dc.description.abstractThe levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and prolactin (PRL) were determined in postoperative premenopausal breast cancer patients. In the patients which received CMF-therapy there was a marked increase in the circulating FSH and LH levels following the initiation of chemotherapy, while in controls the hormone levels remained considerably lower. In contrast, the levels of prolactin decreased appreciably following administration of anticancer drugs to breast cancer patients. A positive correlation was found in these hormonal changes and the regression of tumor size following chemotherapy. The hormone levels in the serum of breast cancer patients can, therefore, serve as clinical tools in monitoring the disease and response to drug treatment.en_US
dc.language.isoen_USen_US
dc.publisherThe Zoological Society of Pakistanen_US
dc.subjectprolactinen_US
dc.subjectAnti-cancer chemotherapyen_US
dc.subjectfollicle stimulating hormoneen_US
dc.subjectluteinizing hormone,en_US
dc.subjectbreast canceren_US
dc.titleEffect of Anti-Cancer Chemotherapy on the Circulating Levels of Follicle Stimulating Hormone, Luteinizing Hormone and Prolactin in Postoperative Premenopausalen_US
dc.typeArticleen_US
dc.Custom.VolumeVol. 23 No. 4, Year 1991-
Appears in Collections:Articles



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.